A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06024174
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986466 — DRUG
    Specified dose on specified days
  • Adagrasib — DRUG
    Specified dose on specified days
  • Cetuximab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

Key Dates

Start date
Nov 9, 2023
Status verified
Jul 2025
Primary completion
May 13, 2024
Completion
May 13, 2024

Study Design

Enrollment
5 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1: DDI Cohort
  • Experimental: Part 1: Dose Escalation
  • Experimental: Part 2: Dose Expansion

Primary Outcome Measure

Part 1: Number of Participants With Dose Limiting Toxicity (DLTs) [ Time Frame: Cycle 1 (Each cycle consist of 28 days) ]

Locations (4)

FacilityCityStateZIPSite coordinators
Local Institution - 0047Los AngelesCalifornia90067-
Local Institution - 0040AthensGeorgia30607-
Local Institution - 0025HackensackNew Jersey07601-
Local Institution - 0008MorristownNew Jersey07960-

Related coverage on Hipa.ai

Find similar trials in Los Angeles, CA

By research site
Local Institution - 0047· Los Angeles, CALocal Institution - 0040· Athens, GALocal Institution - 0025· Hackensack, NJLocal Institution - 0008· Morristown, NJ

Related Studies